Digoxin
Product Images NDC 21695-678

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Digoxin (NDC 21695-678). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Formula (Cabd1834 7398 497e B11f 221a25f21a4e 01)

Chemical structure diagram of Digoxin, showing its steroid core with attached sugar moieties. The illustration depicts the molecular framework characteristic of this cardiac glycoside.*

FDA Label Image

Table 1 (Cabd1834 7398 497e B11f 221a25f21a4e 02)

A data table titled "Comparisons of the Systemic Availability and Equivalent Doses for Oral Preparations of Digoxin". It compares Digoxin products by absolute bioavailability percentages and lists equivalent doses in micrograms across different dosage forms, including tablets, pediatric elixir, solution in capsules, and injection/IV.*

FDA Label Image

Table 2 (Cabd1834 7398 497e B11f 221a25f21a4e 03)

A data table titled 'Times to Onset of Pharmacologic Effect and to Peak Effect of Preparations of Digoxin' listing four digoxin product forms: tablets, elixir pediatric, solution in capsules, and injection/IV. It details their time to onset of effect and time to peak effect in hours or minutes.*

FDA Label Image

Table 3 (Cabd1834 7398 497e B11f 221a25f21a4e 04)

Data table titled 'Subgroup Analyses of Mortality and Hospitalization During the First Two Years Following Randomization' showing risks of all-cause and heart failure-related mortality or hospitalization with placebo versus Digoxin treatment across patient subgroups with various ejection fraction (EF) and cardiac thoracic ratio (CTR) measures. Includes patient counts, event numbers for placebo and Digoxin groups, and relative risk with 95% confidence intervals.*

FDA Label Image

Table 4 (Cabd1834 7398 497e B11f 221a25f21a4e 05)

Data table titled 'Adverse Experiences in Two Parallel, Double-Blind, Placebo-Controlled Withdrawal Trials' reporting number of patients experiencing various adverse effects in Digoxin patients (n=123) versus placebo patients (n=125). Categories include cardiac, gastrointestinal, CNS, and other effects, listing specific symptoms and their occurrence counts in each group.*

FDA Label Image

Table 4 (Cabd1834 7398 497e B11f 221a25f21a4e 06)

A data table titled 'Adverse Experiences in Two Parallel, Double-Blind, Placebo-Controlled Withdrawal Trials' listing the number of patients reporting various adverse experiences among Digoxin patients (n=123) and placebo patients (n=125). It categorizes adverse experiences into Cardiac, Gastrointestinal, CNS, and Other, with numbers indicating patient counts for each adverse effect.*

FDA Label Image

Table 5 (Cabd1834 7398 497e B11f 221a25f21a4e 07)

A table titled 'Usual Daily Maintenance Dose Requirements (mcg) of Digoxin for Estimated Peak Body Stores of 10 mcg/kg' showing dosage in mcg based on corrected creatinine clearance (mL/min per 70 kg) and lean body weight (kg and lb). It also lists the number of days before steady state is achieved if no loading dose is administered, with additional footnotes explaining creatinine clearance adjustments and conversions.*

FDA Label Image

Table 6 (Cabd1834 7398 497e B11f 221a25f21a4e 08)

A data table titled 'Daily Maintenance Doses in Children with Normal Renal Function' showing age groups and corresponding daily maintenance doses of Digoxin in micrograms per kilogram (mcg/kg). The age groups are 2 to 5 years, 5 to 10 years, and over 10 years with respective doses of 10 to 15, 7 to 10, and 3 to 5 mcg/kg.*

FDA Label Image

Digoxin 125mcg (0.125mg) (Cabd1834 7398 497e B11f 221a25f21a4e 09)

Digoxin 125 mcg (0.125 mg) tablets label, showing a quantity of 30 tablets. The label includes the NDC 21695-678-30, mentions the active ingredient strength, and states that each tablet contains 125 mcg Digoxin USP. It is packaged by Physician Partner and manufactured by Jerome Stevens Pharmaceuticals, Inc., Bohemia, NY. The label also includes storage instructions and a caution to keep medication out of the reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.